Premium
Further Experience with Intravenous Immunoglobulin in Women with Recurrent Miscarriage and a Poor Prognosis
Author(s) -
CARP H.J.A.,
AHIRON R.,
MASHIACH S.,
CARP H.J.A.,
TODER V.,
TORCHINSKI A.,
SHOENFELD Y.,
GAZIT E.
Publication year - 2001
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1034/j.1600-0897.2001.d01-12.x
Subject(s) - medicine , miscarriage , antibody , recurrent miscarriage , pregnancy , immunoglobulin g , intravenous immunoglobulins , intravenous immunoglobulin therapy , obstetrics , immunology , biology , genetics
PROBLEM: Women with three or more unexplained miscarriages have a 60% chance of a subsequent live birth. Intravenous immunoglobulin (IVIG) has not been conclusively shown to improve this prognosis. This study assessed the effect of IVIG in patients expected to have a poor outcome if untreated, i.e. women with five or more abortions, who have aborted after paternal leukocyte immunization or who continue to abort despite expressing anti‐paternal complement dependent antibody.
METHODS: Seventy‐six women received IVIG in a dose of 400 mg/kg body weight, in one day (total 30–45 g) in the follicular phase of a cycle in which pregnancy was planned. A booster dose was administered when pregnancy was diagnosed. Their results were compared to an untreated control group of 74 women.
RESULTS: Thirty‐five (49%) pregnancies in treated women have resulted in live births or passed their previous stages of abortion compared to 23 (31%) in control patients ( P =0.04).
CONCLUSIONS: These figures indicate that IVIG may prevent further miscarriages in this poor prognosis population. These figures are especially significant considering the doubt concerning the efficacy of IVIG in patients with three miscarriages and therefore a relatively good prognosis.